Study to elucidate the pharmacological activity of retinalamin in a rat model of ischemic retinopathy

Pobeda, Anna; Kalatanova, A.V.; Abasheva, Daria; Должиков, А. А.; Solovev, Nikolai; Shchurovskaya, Kristina; Chernyaeva, Sofia S.; Колесник, И. М.

doi:10.3897/rrpharmacology.7.67390

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ophthalmoscopy to study the fundus of laboratory rats was performed using a V78C lens, Volk Optical (USA). A detailed description was provided earlier (Pobeda et al 2021). For further statistical processing, the degree of changes in the fundus was assessed in points (Table 1), the points were summed for each criterion for the animal and the data in the group were calculated as the average of all animals in the group.…”

Section: Ophthalmoscopymentioning

confidence: 99%

Neuroprotective properties of Na+/H+-exchanger isoform-1 inhibitor in experimental POAG

Pobeda,

Spasov,

Zhukovskaya

et al. 2023

RRP

View full text Add to dashboard Cite

Introduction: Worldwide glaucoma is the leading cause of irreversible vision loss. The processes associated with the loss of retinal ganglion cells are multifactorial and have much in common with neurodegenerative diseases. Therefore the search for means to prevent the death of retinal neurons is an important task of modern pharmacology. Materials and Methods: The study was conducted on male Wistar rats. Glaucoma was modeled by injecting a 1% solution of hyaluronic acid into the anterior chamber of the eye. The IOP level was recorded on the 0th, 63rd and 73rd days of the experiment. The effectiveness of the drugs was evaluated based on the results of ophthalmoscopy, electroretinography, followed by the determination of gene expression. Results and Discussion: In the group with RU-1355 correction, the fundus picture improved; the index in the group was 18.0% lower compared to the model. The introduction of the RU-1355 compound provided an increase in the a-wave amplitude by 18.1%, and b-wave amplitude by 39.0% relative to the group with pathology. The most pronounced effect was observed on the expression level of BDNF, Bcl-2, Caspase 3 and NF-κB p65, which indicates that the compound has the capacity to influence the slowdown of the apoptosis process through an increase in the neurotrophic factor and the anti-apoptotic factor Bcl-2. Conclusion: RU-1355 has neuroprotective properties, which was expressed by a decrease in ophthalmoscopic manifestations, preservation of the b-wave amplitude of the electroretinogram and the influence on gene expression of factors involved in apoptosis and neuroprotection. Based on the pharmacological activity of the RU-1355 compound in relation to POAG, further study of its action against other retinal diseases is promising.

show abstract

Section: Ophthalmoscopymentioning

confidence: 99%

Neuroprotective properties of Na+/H+-exchanger isoform-1 inhibitor in experimental POAG

Pobeda,

Spasov,

Zhukovskaya

et al. 2023

RRP

View full text Add to dashboard Cite

show abstract

“…Studies show that they can be signaling molecules interacting with specific receptors, as in peptide hormones and cytokines 3,4 . Mesenchymal stem cells are regarded as multipotent adult stem cells in multiple tissues, such as the fat tissue, umbilical cord, as well as bone marrow 5, 6 .…”

Section: Introductionmentioning

confidence: 99%

Conditioned Medium of Induced Mesenchymal Stem Cells as an Activator of Differentiation in The Osteogenic Direction

S.V

V.S

N.A

et al. 2022

Int J Life Sci Pharm Res

View full text Add to dashboard Cite

In the prevailing era, the need for new biologically active substances of peptide nature and their therapeutic impacts are of great interest of the contemporary pharmacology. Hence, this study intends to assess the osteoinductive potential of the conditioned medium concentrate on native mesenchymal stem cells. To gratify the study’s aim, this study was carried out on a culture of rat mesenchymal stem cells. To stimulate the differentiation of Mesenchymal stem cells in the osteogenic direction, this study used a complete nutrient medium containing dexamethasone, ascorbic acid, sodium ß -glycerophosphate in the concentrations recommended in the guidelines. Subsequently, the resulting concentrate sample was examined using HPLC-MS / MS mass, spectrometric analysis. Part of the previously obtained concentrate of the conditioned medium was used, to assess the proliferation and differentiation of rat Mesenchymal stem cells in the osteogenic direction by staining for alkaline phosphatase. Given the results of the study, it can be concluded that that most of the identified proteins of the conditioned medium concentrate belong to the group of proteins regulating cellular processes, and groups of proteins were also, found that relate to the organization of the extracellular structure, the processes of cell development, or are directly responsible for the differentiation of Mesenchymal stem cells in the osteogenic direction. Along with this, the concentrate of the conditioned medium does not affect the proliferation rate of Mesenchymal stem cells. Thus, the resulting concentrate of the conditioned medium, can be further used, for the development of therapeutic preparations with osteoinductive and regenerative potential.

show abstract

Pharmacologic activity of mGLUR4 agonist in a model of primary open-angle glaucoma: A preclinical experimental study

Pobeda

2024

Kuban. nauсh. med. vestnik

View full text Add to dashboard Cite

Background. Worldwide, more than 67 million people suffer from glaucoma. In Russia, this number exceeds 1.08 million people. Annually, the number of primary cases increases by 3–4%. The increasing prevalence of glaucoma intensifies the search for neuroprotectants that can reduce the loss of retinal ganglion cells, thereby impeding the progression of the disease. Objective. To study of the pharmacological activity of mGLUR4 agonist, ZC64-0001 substance, on a model of primary open-angle glaucoma. Methods. The conducted preclinical study involved 60 sexually mature male Wistar rats, weighing 180–220 g. The observation period was 73 days. The animals were divided into 6 groups with 10 animals in each. Group 1 included intact animals (without any manipulations); Group 2 included negative control animals with the water injected in the anterior chamber of the eye; in Group 3–6, primary open-angle glaucoma was modelled by injecting 1% hyaluronic acid solution into the anterior chamber of the eye once every 7 days from day 1 to day 62 of the study. Animals in Group 4 were treated intragastrically with H-[(4-chlorophenyl)methyl]-1,6-dihydro-4-methoxy-1-(2-methylphenyl)-6-oxo-3-pyridazinecarboxamide under the laboratory code of ZC64-0001 at a dose of 10 mg/kg. Animals in Group 5 received Mexidol as a comparison drug intramuscularly at a dose of 25.7 mg/kg. Animals in Group 6 were treated with a Timolol instillation at a dose of 0.009 ml/kg. The studied compounds were administered from day 63 of the study once a day for 10 days. The evaluated indicators included the level of microcirculation in the retina, the amplitude of a-wave and b-wave of the electroretinogram, and the number of retinal ganglionic layer nuclei in the setting of the conducted treatment. Statistical processing of the data was performed using the Statistica 10.0 software (StatSoft, USA). Differences were determined at the significance level of p ˂ 0.05. Results. ZC64-0001 increased the level of microcirculation relative to the group with modelled glaucoma by 11.5%, with this indicator being statistically significantly different from that both in the group with modelled glaucoma and the intact group ( р < 0.05). In the group of animals receiving ZC64-0001, the amplitude of a-wave increased relative to the primary glaucoma group by 17.7%, with this index being statistically different from the groups of intact animals and negative control (р < 0.05). The b-wave amplitude increased by 34.4% relative to the group with modelled glaucoma, being statistically different from the intact group, negative control group, pathology modelled group, and comparison drug groups ( р < 0.05). Administration of ZC64-0001 increased the number of retinal ganglion cell nuclei relative to the group with modelled glaucoma by 41.0%, which had a statistically significant difference from all the studied groups ( р < 0.05). Conclusion. The ZC64-0001 compound demonstrated high neuroprotective properties in a model of primary open-angle glaucoma, leading to an improvement in retinal microcirculation, an increase in the wave amplitude according to the conducted electrophysiological study, and an increase in the number of ganglion cell nuclei.

show abstract

Study to elucidate the pharmacological activity of retinalamin in a rat model of ischemic retinopathy

Cited by 3 publications

References 24 publications

Neuroprotective properties of Na+/H+-exchanger isoform-1 inhibitor in experimental POAG

Neuroprotective properties of Na+/H+-exchanger isoform-1 inhibitor in experimental POAG

Conditioned Medium of Induced Mesenchymal Stem Cells as an Activator of Differentiation in The Osteogenic Direction

Pharmacologic activity of mGLUR4 agonist in a model of primary open-angle glaucoma: A preclinical experimental study

Contact Info

Product

Resources

About